BC Week In Review | Apr 27, 2015
Clinical News

PER977 regulatory update

FDA granted Fast Track designation to PER977 from Perosphere for anticoagulant reversal. The company said it plans to start a Phase III trial and submit a rolling NDA to FDA for the compound in the...
BC Innovations | Dec 11, 2014
Cover Story

Universal reversal for heparin

Titrating heparin treatment is a balancing act for hematologists trying to control blood coagulation without causing excessive bleeding. A synthetic heparin reversal agent from The University of British Columbia uses a dendritic polymer to neutralize...
BC Week In Review | Apr 29, 2013
Company News

Perosphere, Daiichi Sankyo deal

Daiichi Sankyo will co-sponsor a Phase I trial evaluating Perosphere's PER977 to reverse the anticoagulant activity of Daiichi Sankyo's edoxaban. PER977 is a small molecule that binds with heparin and related anticoagulant drugs. Edoxaban, an...
Items per page:
1 - 3 of 3